For example, p53 can upregulate PD-L1 to enhance efficacy of anti-PD-L1 and anti-PD-1 ICI, but this effect varies across cancer type (Wang Y. et al., 2018; Yadollahi et al., 2021). Here, PDCD1 is linked to cancer.